Hemophilia and rare disease specialist Swedish Orphan Biovitrum AB (Sobi) has garnered support from its board of directors and two major investors to take the company private in an $8.1bn buyout that will enable the company to aggressively pursue its growth strategy without pressure from public company investors as it navigates commercial product pressures and potential drug development challenges.
The Sobi board unanimously recommended on 2 September that shareholders accept a SEK69.4bn ($8.1bn) buyout offer from Agnafit Bidco AB, consisting of the private equity firm Advent International and Aurora Investment Pte Ltd, an affiliate of the Singapore sovereign wealth fund GIC Pte Ltd